IL-1 inhibitors were chosen as first-line therapy in MAS more frequently by rheumatologists compared with haemato-oncologists, while etoposide was more frequently the second-line choice of haemato-oncologists. This evidence concerns the gene IL1B and macrophage activation syndrome.